- Home
- NVNI vs LPCN Comparison
NVNI vs LPCN Comparison
Compare NVNI & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNI
- LPCN
- Stock Information
- Founded
- NVNI 2019
- LPCN 1997
- Country
- NVNI Brazil
- LPCN United States
- Employees
- NVNI N/A
- LPCN N/A
- Industry
- NVNI
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- NVNI
- LPCN Health Care
- Exchange
- NVNI Nasdaq
- LPCN Nasdaq
- Market Cap
- NVNI 42.9M
- LPCN 36.8M
- IPO Year
- NVNI N/A
- LPCN N/A
- Fundamental
- Price
- NVNI $0.64
- LPCN $4.98
- Analyst Decision
- NVNI
- LPCN Strong Buy
- Analyst Count
- NVNI 0
- LPCN 1
- Target Price
- NVNI N/A
- LPCN $10.00
- AVG Volume (30 Days)
- NVNI 643.6K
- LPCN 30.1K
- Earning Date
- NVNI 12-31-2024
- LPCN 11-07-2024
- Dividend Yield
- NVNI N/A
- LPCN N/A
- EPS Growth
- NVNI N/A
- LPCN N/A
- EPS
- NVNI N/A
- LPCN N/A
- Revenue
- NVNI $23,558,620.00
- LPCN $7,922,926.00
- Revenue This Year
- NVNI $25.91
- LPCN N/A
- Revenue Next Year
- NVNI $17.52
- LPCN N/A
- P/E Ratio
- NVNI N/A
- LPCN N/A
- Revenue Growth
- NVNI 38.59
- LPCN N/A
- 52 Week Low
- NVNI $0.33
- LPCN $2.44
- 52 Week High
- NVNI $3.20
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- NVNI 46.09
- LPCN 50.88
- Support Level
- NVNI $0.33
- LPCN $4.70
- Resistance Level
- NVNI $0.66
- LPCN $5.28
- Average True Range (ATR)
- NVNI 0.16
- LPCN 0.32
- MACD
- NVNI -0.02
- LPCN 0.04
- Stochastic Oscillator
- NVNI 26.40
- LPCN 69.53
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.